Outpatient vs. Inpatient Liver Cancer Treatment Study
Part of Cancer, Digestive system clinical trials.
This study compares having your liver cancer treatment (TACE or TARE) as an outpatient versus staying in the hospital overnight. It's for people with primary liver cancer whose liver and kidney function are good enough and who can safely go home the same day with support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a type of primary liver cancer called HCC (hepatocellular carcinoma) or iCCA (intrahepatic cholangiocarcinoma)
- You are eligible for a treatment called TACE (chemoembolization) or TARE (radioembolization) without having had the same type before
- Your liver function is relatively good (Child-Pugh score less than B8 for TACE, or bilirubin below a certain level for TARE)
- Your kidneys are working well (clearance above 30 ml/min)
- You can arrange for a responsible adult to stay with you the first night after treatment and have access to urgent care if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.